Evidence map›Paper›PMID 32424805›Full record

ArticleAdvances in therapy2020

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.

Robin K Kelley, Patrick Mollon, Jean-Frédéric Blanc, Bruno Daniele, Thomas Yau, Ann-Lii Cheng, Velichka Valcheva, Florence Marteau, Ines Guerra, Ghassan K Abou-Alfa

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 6 countries.

Robin K KelleyUCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. katie.kelley@ucsf.edu.ORCID https://orcid.org/0000-0002-1984-2430
Patrick MollonIpsen Pharma, Boulogne-Billancourt, France.
Jean-Frédéric BlancHôpital Haut-Lévêque, CHU de Bordeaux, Bordeaux, France.ORCID https://orcid.org/0000-0001-6172-9485
Bruno DanieleAzienda Ospedaliera G Rummo, Benevento, Italy.
Thomas YauUniversity of Hong Kong, Pokfulam, Hong Kong.ORCID https://orcid.org/0000-0002-5221-9755
Ann-Lii ChengNational Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan, Republic of China.ORCID https://orcid.org/0000-0002-9152-6512
Velichka ValchevaIpsen Pharma, Boulogne-Billancourt, France.ORCID https://orcid.org/0000-0002-3476-0046
Florence MarteauIpsen Pharma, Boulogne-Billancourt, France.
Ines GuerraIQVIA Ltd, London, UK.
Ghassan K Abou-AlfaMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-1522-8054
Ipsen (France) · FRAzienda Ospedaliera G.Rummo · ITCentre Hospitalier Universitaire de Bordeaux · FRIQVIA (United Kingdom) · GBMemorial Sloan Kettering Cancer Center · USNational Taiwan University Hospital · TWUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Hong Kong · HK

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundNo trials have compared cabozantinib and regorafenib for the second-line treatment of advanced hepatocellular carcinoma (HCC).

objectivesConduct a matching-adjusted indirect comparison (MAIC) of the efficacy and safety of second-line cabozantinib and regorafenib in patients with advanced HCC and disease progression after prior sorafenib.

methodsThe CELESTIAL and RESORCE trials were used for indirect comparison of second-line cabozantinib and regorafenib in advanced HCC. Population-level data were available for RESORCE, individual patient data (IPD) for CELESTIAL. To align with RESORCE, the CELESTIAL population was limited to patients who received first-line sorafenib only. To minimize potential effect-modifying population differences, the CELESTIAL IPD were weighted to balance the distribution of clinically relevant baseline characteristics with those of RESORCE. Overall survival (OS) and progression-free survival (PFS) were evaluated for the matching-adjusted second-line CELESTIAL population and compared with those for RESORCE using weighted Kaplan-Meier curves and parametric modeling. Rates of grade 3/4 treatment-emergent adverse events (TEAEs) affecting > 5% of patients in any study arm were compared.

resultsIn the matching-adjusted second-line populations (CELESTIAL, effective sample size = 266; RESORCE, n = 573), median (95% confidence interval) OS was similar for cabozantinib and regorafenib (11.4 [8.9-17.0] versus 10.6 [9.1-12.1] months; p = 0.3474, log-rank test). Median PFS was longer for cabozantinib than regorafenib (5.6 [4.9-7.3] versus 3.1 [2.8-4.2] months; p = 0.0005, log-rank test). There was a trend for lower rates of some grade 3/4 TEAEs with regorafenib than with cabozantinib, which may reflect the exclusion of sorafenib-intolerant patients from RESORCE but not from CELESTIAL, a difference that the MAIC methods could not remove. Only diarrhea rates were statistically significantly lower for regorafenib (p  ≤ 0.001).

conclusionsCabozantinib may achieve similar OS and prolonged PFS compared with regorafenib in patients with progressive advanced HCC after prior sorafenib.

Indexed as

AnilidesCarcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsPyridinesAngiogenesis InhibitorsAntineoplastic AgentsComparative Effectiveness ResearchDisease ProgressionFemaleHumansMaleMiddle AgedNeoplasm StagingOutcome and Process Assessment, Health CareProgression-Free SurvivalAngiogenesis InhibitorsAnilidesAntineoplastic AgentscabozantinibPhenylurea CompoundsPyridinesregorafenibSorafenibCabozantinibCELESTIALHepatocellular carcinoma (HCC)Indirect treatment comparisonMatching-adjusted indirect comparison (MAIC)RegorafenibRESORCESecond-lineSystemic therapyTargeted therapy

Identifiers

PMID32424805
PMCPMC7467441
OpenAlexW3028471338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.